



Spray Drying of Cubosomes for Oral Vaccine Delivery

von Halling Laier, Christoffer; Abid, Zarmeena; Weydahl, Ingrid Elise Konow; Rades, Thomas; Boisen, Anja; Nielsen, Line Hagner

Publication date:
2016

Document Version
Peer reviewed version

[Link back to DTU Orbit](#)

Citation (APA):
von Halling Laier, C., Abid, Z., Weydahl, I. E. K., Rades, T., Boisen, A., & Nielsen, L. H. (2016). *Spray Drying of Cubosomes for Oral Vaccine Delivery*. Poster session presented at 2016 AAPS Annual Meeting and Exposition, Denver, CO, United States.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Spray Drying of Cubosomes for Oral Vaccine Delivery

Christoffer von Halling Laier¹, Zarmeena Abid¹, Ingrid E.K. Weydahl¹, Thomas Rades², Anja Boisen¹, Line Hagner Nielsen¹

¹Department of Micro and Nanotechnology, Technical University of Denmark, Kgs. Lyngby, Denmark

²Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

2016 AAPS

ANNUAL MEETING AND EXPOSITION

NOVEMBER 13–17, 2016

COLORADO CONVENTION CENTER, DENVER



PURPOSE

To prepare cubosomes carrying the model antigen ovalbumin and the adjuvant Quil A using spray drying as method, as well as to *in vitro* characterize these particles.

METHOD




Fig. 1: 5.33 w/v% Dimodan® MO 90/D (high monoolein content) in ethanol is diluted by adding it to aqueous solution of dextran, ovalbumin (OVA) and Quil A (2.67, 0.13 and 0.14 w/v% respectively). The dilution of the ethanol causes immediate precipitation of lipid particles giving a turbid mixture in 24 v/v % ethanol. The mixture is spray dried on a Büchi mini spray dryer.

ACKNOWLEDGEMENTS



VILLUM FONDEN

DTU Nanotech
Department of Micro- and Nanotechnology



The research is funded by the Danish National Research Foundation (DNRF122) and Villum Fonden (Grant No. 9301).

We acknowledge the Core Facility for Integrated Microscopy, Faculty of Health and Medical Sciences, University of Copenhagen.

RESULTS

Particle Morphology

The spray dried powder was heated to 90°C for 24h. This

- Reduced electrostatic charges in the powder
- Allowed easy reconstitution to a colloidal stable suspension
- Induced weight loss of 8%

The powder was rich in cubosomes after reconstitution (Fig. 2)




Fig. 2: Cubosomes produced from monoolein by a spray drying process. Representative cryo-TEM images of the cubosomes are shown immediately after reconstitution (a+b) and after 12 hours in suspension (c).

Ovalbumin release from cubosomes




Fig. 3: Release kinetics of FITC-OVA from the cubosomes expressed as percent of total loaded FITC-OVA.

Particle Characterization

Table 1: Size and zeta-potential of cubosomes with and without adjuvant as measured by dynamic light scattering in Milli-Q water. Mass median aerodynamic diameter (MMAD) measured by time-of-flight mass spectroscopy.

Formulation	Size (nm)	PDI	Zeta potential (mV)	MMAD (μm)
Cubosomes with OVA	256±10	0.42	-31.7±1.4	4.1±0.4
Cubosomes with OVA and Quil A	233±13	0.24	-38.3±1.7	4.1±0.02

Table 2: OVA content in formulation

OVA content in powder	20.3±0.5 μg/mg
OVA load in particles	5.1±0.1% wt

Loading into microcontainers

Microcontainers were fully and homogeneously filled with cubosome powder by an embossing method. The microcontainers offer the possibility to protect the formulation during passage through the stomach and provide release of the cubosomes in the intestine.




Fig. 4: a+b) SEM image of and empty microcontainer (a) and microcontainers loaded with cubosomes (b). c+d) X-ray microtomography images of the loaded microcontainers.

CONCLUSION

The developed cubosomes show properties suitable to be used for oral vaccine delivery in microcontainers.